



Global Media Contacts:

Christine Lydon

+44-20-7395-7145

christine.lydon@fleishmaneuropa.com

Iva Ng

OrbusNeich

+852 3109-7268

ing@orbusneich.com

**OrbusNeich appoints Alain Aimonetti as Vice President
Global Marketing and Sales EMEA**

Role to support company's growing product portfolio

HONG KONG, [2 March 2015] – OrbusNeich, a global company specialising in innovative coronary devices, today announced the appointment of Alain Aimonetti as Vice President Global Marketing and Sales EMEA. Mr Aimonetti, who has more than 24 years of medical device Marketing, Sales and Business development, will focus on the company's extensive portfolio of high-performance stents and balloons, including the COMBO™ Dual Therapy Stent - the world's first dual therapy stent, launched in 2013.

“We are pleased to welcome Alain to OrbusNeich at a pivotal time as we continue to expand our product portfolio and build on the success of the COMBO Dual Therapy Stent,” said B. Wayne Johnson, President and Chief Executive Officer, OrbusNeich. “We're confident that Alain's experience and broad knowledge, along with his ability to build successful sales and marketing teams, will play a critical role in providing innovative and proven solutions to interventional cardiologists worldwide.”

Prior to joining OrbusNeich, Mr Aimonetti held a variety of senior roles in the cardio- and endovascular medical devices industry. Alain has devoted himself to the vascular intervention field throughout his entire career within the industry. At the earlier stage in 1992, he was the country manager vascular intervention for France, Africa and Canada at Cordis, and was subsequently appointed in 1996 as the global marketing manager at Boston Scientific and the VP of sales and marketing for EMEA at SUTURA BV. His most recent

position was at Biotronik where he was VP Global Sales and Business Development, Vascular Intervention.

“I am extremely excited to join OrbusNeich and look forward to increasing the commercial success and presence, the company have achieved to date,” said Mr Aimonetti.

“My role presents a unique opportunity to grow the business and further drive OrbusNeich’s reputation and credibility as a specialist leader in interventional cardiology, by bringing to market, products with unique features that deliver high value to our customers.”

Mr Aimonetti’s appointment follows the recent naming of Mr Johnson as OrbusNeich President and Chief Executive Officer.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world’s first pro-healing stent, the Genous™ Stent. Other products include stents and balloons marketed under the names of Azule™, R Stent™, Scoreflex™, Sapphire™, Sapphire™, II and Sapphire™ II NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: <http://www.youtube.com/user/OrbusNeichMedia>.

###